Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies

Chronic infection with hepatitis B virus (HBV) represents one of the main causes of the development of cirrhosis and its complications. Treatment with potent third-generation nucleos(t)ide analogues (NUCs) results in >99% HBV DNA undetectability, and prevents fibrosis progression and liver-relate...

Full description

Saved in:
Bibliographic Details
Published inViruses Vol. 14; no. 11; p. 2404
Main Authors Degasperi, Elisabetta, Anolli, Maria Paola, Lampertico, Pietro
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 29.10.2022
MDPI
Subjects
Antigens
Antiviral agents
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Antiviral drugs
Care and treatment
Chronic infection
Cirrhosis
clinical trials
DNA, Viral
Drug development
Drug dosages
Fibrosis
functional cure
Genetic aspects
Genomes
HBV
Hepatitis B
Hepatitis B - drug therapy
Hepatitis B Antibodies
Hepatitis B surface antigen
Hepatitis B Surface Antigens
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Humans
Immunomodulation
investigational drugs
Liver cancer
Liver cirrhosis
Liver diseases
nucleos(t)ide analogues
Physiological aspects
Polypeptides
Proteins
Review
Seroconversion
Signal transduction
Virus Replication
Italy
functional cure
clinical trials
HBV
investigational drugs
nucleos(t)ide analogues
Online AccessGet full text

Cover

Abstract Chronic infection with hepatitis B virus (HBV) represents one of the main causes of the development of cirrhosis and its complications. Treatment with potent third-generation nucleos(t)ide analogues (NUCs) results in >99% HBV DNA undetectability, and prevents fibrosis progression and liver-related complications. However, NUCs are not able to induce the so-called functional cure, which is hepatitis B surface antigen (HBsAg) loss and anti-HBs seroconversion. Consequently, NUC treatment is currently intended as being long-term or lifelong, resulting in the need for clinical monitoring and potentially suffering from compliance issues. Consequently, drug development in HBV has the goal of developing new agents in order to achieve a functional cure for HBV. Currently, the three main strategies include the following: inhibition of viral replication, inhibition of viral antigens, and immune modulation. This review summarizes the most recent updates concerning HBV compounds among these three main classes.
AbstractList Chronic infection with hepatitis B virus (HBV) represents one of the main causes of the development of cirrhosis and its complications. Treatment with potent third-generation nucleos(t)ide analogues (NUCs) results in >99% HBV DNA undetectability, and prevents fibrosis progression and liver-related complications. However, NUCs are not able to induce the so-called functional cure, which is hepatitis B surface antigen (HBsAg) loss and anti-HBs seroconversion. Consequently, NUC treatment is currently intended as being long-term or lifelong, resulting in the need for clinical monitoring and potentially suffering from compliance issues. Consequently, drug development in HBV has the goal of developing new agents in order to achieve a functional cure for HBV. Currently, the three main strategies include the following: inhibition of viral replication, inhibition of viral antigens, and immune modulation. This review summarizes the most recent updates concerning HBV compounds among these three main classes.Chronic infection with hepatitis B virus (HBV) represents one of the main causes of the development of cirrhosis and its complications. Treatment with potent third-generation nucleos(t)ide analogues (NUCs) results in >99% HBV DNA undetectability, and prevents fibrosis progression and liver-related complications. However, NUCs are not able to induce the so-called functional cure, which is hepatitis B surface antigen (HBsAg) loss and anti-HBs seroconversion. Consequently, NUC treatment is currently intended as being long-term or lifelong, resulting in the need for clinical monitoring and potentially suffering from compliance issues. Consequently, drug development in HBV has the goal of developing new agents in order to achieve a functional cure for HBV. Currently, the three main strategies include the following: inhibition of viral replication, inhibition of viral antigens, and immune modulation. This review summarizes the most recent updates concerning HBV compounds among these three main classes.
Chronic infection with hepatitis B virus (HBV) represents one of the main causes of the development of cirrhosis and its complications. Treatment with potent third-generation nucleos(t)ide analogues (NUCs) results in >99% HBV DNA undetectability, and prevents fibrosis progression and liver-related complications. However, NUCs are not able to induce the so-called functional cure, which is hepatitis B surface antigen (HBsAg) loss and anti-HBs seroconversion. Consequently, NUC treatment is currently intended as being long-term or lifelong, resulting in the need for clinical monitoring and potentially suffering from compliance issues. Consequently, drug development in HBV has the goal of developing new agents in order to achieve a functional cure for HBV. Currently, the three main strategies include the following: inhibition of viral replication, inhibition of viral antigens, and immune modulation. This review summarizes the most recent updates concerning HBV compounds among these three main classes.
Audience Academic
Author Degasperi, Elisabetta
Anolli, Maria Paola
Lampertico, Pietro
AuthorAffiliation 2 CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy
1 Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
AuthorAffiliation_xml – name: 1 Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
– name: 2 CRC “A. M. and A. Migliavacca” Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy
Author_xml – sequence: 1
  givenname: Elisabetta
  orcidid: 0000-0002-9899-4669
  surname: Degasperi
  fullname: Degasperi, Elisabetta
– sequence: 2
  givenname: Maria Paola
  surname: Anolli
  fullname: Anolli, Maria Paola
– sequence: 3
  givenname: Pietro
  orcidid: 0000-0002-1026-7476
  surname: Lampertico
  fullname: Lampertico, Pietro
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36366502$$D View this record in MEDLINE/PubMed
BookMark eNptkstu1DAYhS1URC-w4AWQJTawmNZ3xyyQhhGllSpY0LJgYzm-DB5l4qmdTMXb4-m0pVNQIsX6850v-qNzCPb61HsAXmN0TKlCJ2vMMCYMsWfgACulJkxhvvfovA8OS1kgJIRC8gXYp4IKwRE5AD8v043JrkADT8feDjH1poOzMXsYUoZnfmWGOMQCP8EfMY_lA5xCggiBVytnBg9TD7_6Gzjth7iOuUa_D7nO59GXl-B5MF3xr-6eR-Dq9PPl7Gxy8e3L-Wx6MbGcimHStsw6E9qGGmGdE7iRQUlvqKw3Cdw4ZtogJTFOicBFwwKqGW6CEESoQI_A-dbrklnoVY5Lk3_rZKK-HaQ81yYP0XZec484tcQ11kiGhVICISyCb7BskGpldX3culZju_TO-r6u0-1Id9_08Zeep7VWVYZYUwXv7gQ5XY--DHoZi_VdZ3qfxqKJpLwRsiG8om-foIs05vr7bykmOaUc_aXmpi4Q-5Dqd-1GqqeSCYklIaJSx_-h6uX8MtralhDrfCfw5vGiDxveN6MCJ1vA5lRK9kHbOJhNP6o5dhojvemefuheTbx_kriX_sv-AY7u1Pw
CitedBy_id crossref_primary_10_1016_j_jve_2023_100354
crossref_primary_10_3390_pathogens13010046
crossref_primary_10_3748_wjg_v30_i10_1295
crossref_primary_10_1002_med_22030
crossref_primary_10_2196_56426
crossref_primary_10_1111_liv_16213
crossref_primary_10_3389_fonc_2023_1143258
crossref_primary_10_1021_acs_jmedchem_3c01022
crossref_primary_10_20517_2394_4722_2023_147
crossref_primary_10_2147_IJGM_S480283
crossref_primary_10_1097_CLD_0000000000000134
crossref_primary_10_3390_molecules29122942
crossref_primary_10_1080_13543776_2025_2467699
crossref_primary_10_3390_microorganisms11030600
Cites_doi 10.1111/jvh.12942
10.1016/j.cld.2021.07.001
10.1016/j.jhep.2017.03.021
10.1053/j.gastro.2020.02.058
10.1016/S0168-8278(22)00537-2
10.1136/gutjnl-2015-309809
10.3390/v9040075
10.1053/j.gastro.2009.08.063
10.1016/S0168-8278(22)00541-4
10.1002/hep.22881
10.1021/acsinfecdis.8b00269
10.1016/S0140-6736(12)61425-1
10.1111/liv.13142
10.1016/S0168-8278(22)02024-4
10.1016/S0168-8278(22)02045-1
10.1016/S0168-8278(22)02041-4
10.1016/S0168-8278(22)00437-8
10.1016/S0168-8278(22)00538-4
10.1016/S0168-8278(22)02029-3
10.1111/liv.13253
10.1016/S0168-8278(22)01967-5
10.1016/S0168-8278(22)02054-2
10.1016/j.jhep.2022.03.006
10.1016/S0168-8278(22)01968-7
10.1002/hep.23785
10.1016/j.jhep.2015.01.002
10.1055/s-0033-1345717
10.1016/S0168-8278(22)01959-6
10.1016/S0168-8278(22)01994-8
10.1016/S0168-8278(22)00964-3
10.1016/S0168-8278(22)00444-5
10.1016/j.jhep.2015.06.006
10.1016/S0168-8278(22)02030-X
ContentType Journal Article
Copyright COPYRIGHT 2022 MDPI AG
2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022 by the authors. 2022
Copyright_xml – notice: COPYRIGHT 2022 MDPI AG
– notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022 by the authors. 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7U9
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.3390/v14112404
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Virology and AIDS Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
CrossRef
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1999-4915
ExternalDocumentID oai_doaj_org_article_5e053c2d8ca74169960016fe817809b7
PMC9699048
A746717226
36366502
10_3390_v14112404
Genre Journal Article
Review
GeographicLocations Italy
GeographicLocations_xml – name: Italy
GroupedDBID ---
2WC
53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACUHS
AFKRA
AFPKN
AFZYC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
DIK
E3Z
EBD
ESX
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IHR
ITC
KQ8
LK8
M1P
M48
M7P
MODMG
M~E
O5R
O5S
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RPM
TR2
TUS
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7U9
7XB
8FK
AZQEC
DWQXO
GNUQQ
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c536t-bb4cdafb83a6cdd6187f97ea37a372f5ad4abf772ad96f5684f0bb45af66269f3
IEDL.DBID M48
ISSN 1999-4915
IngestDate Wed Aug 27 01:29:34 EDT 2025
Thu Aug 21 18:39:24 EDT 2025
Mon Jul 21 12:02:13 EDT 2025
Fri Jul 25 12:04:44 EDT 2025
Tue Jun 17 22:10:39 EDT 2025
Tue Jun 10 21:09:34 EDT 2025
Thu Apr 03 07:08:42 EDT 2025
Tue Jul 01 02:48:41 EDT 2025
Thu Apr 24 23:03:53 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords functional cure
clinical trials
HBV
investigational drugs
nucleos(t)ide analogues
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c536t-bb4cdafb83a6cdd6187f97ea37a372f5ad4abf772ad96f5684f0bb45af66269f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-9899-4669
0000-0002-1026-7476
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/v14112404
PMID 36366502
PQID 2734753350
PQPubID 2032319
ParticipantIDs doaj_primary_oai_doaj_org_article_5e053c2d8ca74169960016fe817809b7
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9699048
proquest_miscellaneous_2735867825
proquest_journals_2734753350
gale_infotracmisc_A746717226
gale_infotracacademiconefile_A746717226
pubmed_primary_36366502
crossref_citationtrail_10_3390_v14112404
crossref_primary_10_3390_v14112404
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20221029
PublicationDateYYYYMMDD 2022-10-29
PublicationDate_xml – month: 10
  year: 2022
  text: 20221029
  day: 29
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Viruses
PublicationTitleAlternate Viruses
PublicationYear 2022
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Agarwal (ref_23) 2022; 77
Nassal (ref_11) 2015; 64
Hou (ref_18) 2022; 77
Agarwal (ref_36) 2022; 77
ref_12
Gane (ref_20) 2022; 77
Zhang (ref_15) 2019; 5
Su (ref_6) 2016; 36
Yuen (ref_22) 2022; 77
Bazinet (ref_30) 2020; 158
Marcellin (ref_8) 2013; 381
Lim (ref_26) 2022; 77
Wang (ref_35) 2022; 77
Lim (ref_28) 2022; 77
Lampertico (ref_5) 2015; 63
Loglio (ref_13) 2021; 25
Liang (ref_9) 2009; 49
Yuen (ref_27) 2022; 77
Agarwal (ref_31) 2018; 25
Sulkowski (ref_16) 2022; 77
Agarwal (ref_24) 2022; 77
Raffetti (ref_3) 2016; 36
Yuen (ref_25) 2022; 77
Yuen (ref_19) 2022; 77
ref_21
Janssen (ref_32) 2021; 75
Papatheodoridis (ref_4) 2015; 62
Evans (ref_33) 2022; 77
Glebe (ref_10) 2013; 33
ref_1
Yuen (ref_17) 2022; 77
You (ref_29) 2022; 77
Slaets (ref_34) 2022; 77
ref_2
Chang (ref_7) 2010; 52
Zoulim (ref_14) 2009; 137
References_xml – volume: 25
  start-page: 1331
  year: 2018
  ident: ref_31
  article-title: Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment
  publication-title: J. Viral. Hepat.
  doi: 10.1111/jvh.12942
– volume: 25
  start-page: 875
  year: 2021
  ident: ref_13
  article-title: Novel therapies that may cure chronic hepatitis B
  publication-title: Clin. Liver Dis.
  doi: 10.1016/j.cld.2021.07.001
– ident: ref_2
  doi: 10.1016/j.jhep.2017.03.021
– volume: 158
  start-page: 2180
  year: 2020
  ident: ref_30
  article-title: Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients with Chronic HBV Infection Naïve to Nucleos(t)ide Therapy
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.02.058
– volume: 77
  start-page: S69
  year: 2022
  ident: ref_26
  article-title: Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)00537-2
– volume: 64
  start-page: 1972
  year: 2015
  ident: ref_11
  article-title: HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B
  publication-title: Gut
  doi: 10.1136/gutjnl-2015-309809
– ident: ref_12
  doi: 10.3390/v9040075
– ident: ref_1
– volume: 137
  start-page: 1593
  year: 2009
  ident: ref_14
  article-title: Hepatitis B virus resistance to nucleos(t)ide analogues
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2009.08.063
– volume: 77
  start-page: S72
  year: 2022
  ident: ref_34
  article-title: Therapeutic vaccine JNJ-0535 induces a strong HBV-specific T-cell response in healthy adults and a modest response in chronic HBV infected patients
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)00541-4
– ident: ref_21
– volume: 49
  start-page: S13
  year: 2009
  ident: ref_9
  article-title: Hepatitis B: The virus and disease
  publication-title: Hepatology
  doi: 10.1002/hep.22881
– volume: 5
  start-page: 759
  year: 2019
  ident: ref_15
  article-title: Discovery of novel hepatitis B virus nucleocapsid assembly inhibitors
  publication-title: ACS Infect. Dis.
  doi: 10.1021/acsinfecdis.8b00269
– volume: 381
  start-page: 468
  year: 2013
  ident: ref_8
  article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)61425-1
– volume: 36
  start-page: 1239
  year: 2016
  ident: ref_3
  article-title: Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: A systematic review and metaanalysis
  publication-title: Liver Int.
  doi: 10.1111/liv.13142
– volume: 77
  start-page: S864
  year: 2022
  ident: ref_22
  article-title: Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): Results from the REEF-1 study
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)02024-4
– volume: 77
  start-page: S876
  year: 2022
  ident: ref_25
  article-title: Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)02045-1
– volume: 77
  start-page: 873
  year: 2022
  ident: ref_29
  article-title: Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)02041-4
– volume: 77
  start-page: S8
  year: 2022
  ident: ref_23
  article-title: Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: Results from REEF-2 study
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)00437-8
– volume: 77
  start-page: S70
  year: 2022
  ident: ref_35
  article-title: ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: Interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PDL1 Ab ASC22 (Envafolimab) plus nucleos (t)ide analogs
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)00538-4
– volume: 77
  start-page: S867
  year: 2022
  ident: ref_17
  article-title: Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and naïve chronic hepatitis B patients: 48-week treatment and posttreatment follow-up
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)02029-3
– volume: 36
  start-page: 1755
  year: 2016
  ident: ref_6
  article-title: Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
  publication-title: Liver Int.
  doi: 10.1111/liv.13253
– volume: 77
  start-page: S835
  year: 2022
  ident: ref_19
  article-title: Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)01967-5
– volume: 77
  start-page: S880
  year: 2022
  ident: ref_28
  article-title: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection not on stable nucleos (t)ide analogue therapy: Interim results from the randomised phase 2b B-Clear study
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)02054-2
– volume: 77
  start-page: 245
  year: 2022
  ident: ref_24
  article-title: A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV ‘cure’
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2022.03.006
– volume: 77
  start-page: S836
  year: 2022
  ident: ref_16
  article-title: Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)01968-7
– volume: 52
  start-page: 886
  year: 2010
  ident: ref_7
  article-title: Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
  publication-title: Hepatology
  doi: 10.1002/hep.23785
– volume: 62
  start-page: 956
  year: 2015
  ident: ref_4
  article-title: Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2015.01.002
– volume: 33
  start-page: 103
  year: 2013
  ident: ref_10
  article-title: The molecular virology of hepatitis B virus
  publication-title: Semin. Liver Dis.
  doi: 10.1055/s-0033-1345717
– volume: 77
  start-page: S831
  year: 2022
  ident: ref_36
  article-title: Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)01959-6
– volume: 77
  start-page: S848
  year: 2022
  ident: ref_20
  article-title: Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB)
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)01994-8
– volume: 77
  start-page: S299
  year: 2022
  ident: ref_18
  article-title: Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)00964-3
– volume: 77
  start-page: S13
  year: 2022
  ident: ref_27
  article-title: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos (t)ide analogue therapy: Interim results from the randomised phase 2b B-Clear study
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)00444-5
– volume: 63
  start-page: 1118
  year: 2015
  ident: ref_5
  article-title: The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2015.06.006
– volume: 75
  start-page: S757
  year: 2021
  ident: ref_32
  article-title: Safety and efficacy of oral TLR8 agonist selgantolimod in viremic adult patients with chronic hepatitis B
  publication-title: J. Hepatol.
– volume: 77
  start-page: S868
  year: 2022
  ident: ref_33
  article-title: Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos (t)ide analogues
  publication-title: J. Hepatol.
  doi: 10.1016/S0168-8278(22)02030-X
SSID ssj0066907
Score 2.3914123
SecondaryResourceType review_article
Snippet Chronic infection with hepatitis B virus (HBV) represents one of the main causes of the development of cirrhosis and its complications. Treatment with potent...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2404
SubjectTerms Antigens
Antiviral agents
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Antiviral drugs
Care and treatment
Chronic infection
Cirrhosis
clinical trials
DNA, Viral
Drug development
Drug dosages
Fibrosis
functional cure
Genetic aspects
Genomes
HBV
Hepatitis B
Hepatitis B - drug therapy
Hepatitis B Antibodies
Hepatitis B surface antigen
Hepatitis B Surface Antigens
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Humans
Immunomodulation
investigational drugs
Liver cancer
Liver cirrhosis
Liver diseases
nucleos(t)ide analogues
Physiological aspects
Polypeptides
Proteins
Review
Seroconversion
Signal transduction
Virus Replication
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlUOgl9JXGbVrUUkguJmu9bPe2CVmWHnrKlpCL0JMuFG9Y7xb67ztj2WZNC70EfLJGWBqNNN-Y0TeEfJYqsMJXJpfgAHIhbZkbYTAFykdmPTcsdAmy39RyJb7eybuDUl-YE5bogZPiLiXWLnDMV84geEAyEUApMVRFWc1q290jB583BFPpDFYY8yUeIQ5B_eWvQgCuEH01tsH7dCT9fx_FB75omid54HgWz8lxjxjpPI30BXkSmpfkaaoh-fsVub_tEl9baugCfFT6tUev99tAAY_SZcCU6d26pVf0-3q7b7_QOWXgUunqAYN9umkoHHR03mAZCfg8HfhqQ_uarBY3t9fLvC-YkDvJ1S63Vjhvoq24Uc57VVRlrMtgeAkPi9J4YWwEPG18raJUlYgz6CNNVBDX1JGfkKNm04RTQlW0ZRFmEQCSEJ7LmjsPPWQNS-6hd0YuBkVq17OJY1GLnxqiCtS5HnWekU-j6EOi0PiX0BWuxiiArNfdC7AF3duC_p8tZOQc11Lj3oTBONNfMYApIcuVnmNtFUBsDIZ_NpGEPeWmzYM16H5PtxqJgCC443KWkY9jM_bEPLUmbPadjKzA_zOZkTfJeMYpccUV4GGWkXJiVpM5T1ua9Y-O8buGucJR-_YxlPSOPEMrQ__L6jNytNvuw3sAVjv7odtDfwC30x3k
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Li9RAEG50RfAivo2u0oqgl7CTfiXZyzK7OAwePO3I4CX00x2QZJzMCP57q5JO3OCykNN0NelHVddXnZqvCPkglWeZK3QqwQGkQpo81UJjCpQLzDiume8SZL-q5Up8Wct1vHBrY1rlcCZ2B7VrLN6RnyANC0BrLmdn218pVo3Cr6uxhMZdcg-py1Cr8_UYcCmM_Ho2IQ6h_cnvTAC6ELEm2-CDOqr-_w_kax5pmi15zf0sHpGHETfSeb_Rj8kdXz8h9_tKkn-eku-XXfprSzVdgKfqL_joxWHnKaBSuvSYOL3ftPScftvsDu0pnVMGjpWuthjy06amcNzReY3FJOD1dGCt9e0zslp8vrxYprFsQmolV_vUGGGdDqbgWlnnVFbkocy95jk8LEjthDYBULV2pQpSFSLMoI_UQUF0Uwb-nBzVTe1fEqqCyTM_CwCThHBcltw66CFL2HgHvRPyaVjIykZOcSxt8bOC2ALXvBrXPCHvR9FtT6Rxk9A57sYogNzX3Q_N7kcVTamSWM3CMldYjXAS6WUAtwZfZHkxK02ekI-4lxVaKAzG6vhHA5gScl1Vc6ywAriNwfCPJ5JgWXbaPGhDFS27rf7pYULejc3YE7PVat8cOhlZAApgMiEveuUZp8QVV4CKWULyiVpN5jxtqTdXHe93CXOFA_fV7cN6TR6g_qB_ZeUxOdrvDv4NAKe9edtZx1_jcRa0
  priority: 102
  providerName: ProQuest
Title Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies
URI https://www.ncbi.nlm.nih.gov/pubmed/36366502
https://www.proquest.com/docview/2734753350
https://www.proquest.com/docview/2735867825
https://pubmed.ncbi.nlm.nih.gov/PMC9699048
https://doaj.org/article/5e053c2d8ca74169960016fe817809b7
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9NAEB_OOwRfxG9znmUVQV-izWY_EkGkPa4WwUPkKsWXsMnuauFI75JWvP_emSQNF7wHoeShO0Oyu7M7M5vJ7wfwSirHI5uYUKIDCIXMdWiEoRIo63luY8NdUyB7quYL8Xkpl3uw49jsBrC-MbUjPqlFdf72z-XVR1zwHyjjxJT93e9IYNQgCBX0AB2SJiKDL6J_maAoAWxeLqdEqBbJFmBoqDpwSw16_7979DUnNSygvOaRZvfgbhdKskk79_dhz5UP4HZLLnn1EH6cNRWxNTNshs6rPfNjx9vKMQxU2dxRLfVmVbMp-76qtvV7NmEcfS1bXNApAFuXDHdANimJXwJvz3ZAtq5-BIvZydnxPOyYFMJCxmoT5rkorPF5EhtVWKuiRPtUOxNr_HEvjRUm9xhoG5sqL1Ui_Bh1pPEKE57Ux49hv1yX7ikw5XMdubHHyEkIG8s0LixqyBRtwaJ2AG92A5kVHcw4sV2cZ5hu0Jhn_ZgH8LIXvWixNW4SmtJs9AIEh938sa5-Zt3qyiQRXBTcJoWhCJMQZzCU9S6JdDJOcx3Aa5rLjMwIH6Yw3bcH2CWCv8omRLqChsPx8Y8GkrjYimHzzhqyna1mhBCEWV8sxwG86JtJkwrYSrfeNjIywcCAywCetMbTdylWscJAmQegB2Y16POwpVz9aqDAU-wr7sGH_92_Z3CHTIm8L0-PYH9Tbd1zDKs2-Qhu6aUewcH05PTrt1FzOIHXT8to1CynvzgBIow
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIQQviG8CAwwCwUu01I6dBAmhblB1bOypRdVeghPbWyWUlqYF7Z_ib-QuXywC8TapT_W59cf57nfO5X4AL6WyfGBi7Ut0AH4os8jXoaYUKON4ZoTmtkqQPVbjafhpJmdb8Kt9F4bSKlubWBlqs8jpjnyXyrAgtBYyeL_87hNrFD1dbSk0arU4tOc_MWQr3x18wP19xfno42R_7DesAn4uhVr7WRbmRrssFlrlxqhBHLkkslpE-OFOahPqzCHo1CZRTqo4dAH2kdopBP-JE_i7V-AqOt6Agr1o1gV4iiLNunqREEmw-2MQIpoJGw641udV1AB_O4ALHrCfnXnB3Y1uwc0Gp7JhrVi3YcsWd-BazVx5fhdOJlW6bck0G6FnrC8U2f5mZRmiYDa2lKi9npdsj32ZrzblWzZkHB05my7pioEtCobmlQ0LIq_Av2dtlVxb3oPppSzofdguFoV9CEy5LBrYwCEsC0MjZCJygz1kgopmsLcHb9qFTPOmhjlRaXxLMZahNU-7NffgRSe6rAt3_Etoj3ajE6Ba29UXi9Vp2hzdVBJ7Rs5NnGuCr1TOBnGys_EgioMkizx4TXuZkkXAweS6ebEBp0S1tdIhMbogTuQ4_J2eJJ7kvN_cakPaWJIy_aP3HjzvmqknZccVdrGpZGSMqINLDx7UytNNSSihEIVzD6KeWvXm3G8p5mdVnfEE54oG_tH_h_UMro8nn4_So4Pjw8dwg3SJfDtPdmB7vdrYJwja1tnT6qQw-HrZR_M3sOpVvw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4anUC8IO4EBhgEgpeorR07CRJC7baqY6ia0IqmvQQntrdKKC1NC9pf49dxTi5lEYi3SX2q7daXc_mOc3I-gFdSWd43kfYlOgA_kGno60BTCpRxPDVCc1smyE7UeBp8PJEnW_CreReG0iobm1gaajPP6I68S2VYEFoL2eu6Oi3iaG_0YfHdJwYpetLa0GlUInJoL35i-Fa8P9jDs37N-Wj_eHfs1wwDfiaFWvlpGmRGuzQSWmXGqH4Uuji0WoT44U5qE-jUIQDVJlZOqihwPRwjtVMYCMRO4O9eg-2QoqIObA_3J0efGz-gKO6sahkJEfe6P_oBYpugZoRrPGBJFPC3O7jkD9u5mpec3-g23KpRKxtUYnYHtmx-F65XPJYX9-D0uEy-LZhmI_ST1fUi210vLUNMzMaW0rZXs4IN2ZfZcl28YwPG0a2z6YIuHNg8Z2hs2SAnKgv8e9bUzLXFfZheyZY-gE4-z-0jYMqlYd_2HIK0IDBCxiIzOELGKHYGR3vwttnIJKsrmhOxxrcEIxva82Sz5x683HRdVGU8_tVpSKex6UCVt8sv5suzpFbkRBKXRsZNlGkCs1TcBlGzs1E_jHpxGnrwhs4yIfuAk8l0_ZoDLokqbSUD4ndB1Mhx-jutnqjXWbu5kYaktitF8kcLPHixaaaRlCuX2_m67CMjxCBcevCwEp7NkoQSCjE59yBsiVVrze2WfHZeVh2Pca1o7h__f1rP4QaqZfLpYHL4BG6SKJGj5_EOdFbLtX2KCG6VPqtVhcHXq9bO31g3W1o
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Towards+a+Functional+Cure+for+Hepatitis+B+Virus%3A+A+2022+Update+on+New+Antiviral+Strategies&rft.jtitle=Viruses&rft.au=Degasperi%2C+Elisabetta&rft.au=Anolli%2C+Maria+Paola&rft.au=Lampe&rft.date=2022-10-29&rft.pub=MDPI+AG&rft.issn=1999-4915&rft.eissn=1999-4915&rft.volume=14&rft.issue=11&rft_id=info:doi/10.3390%2Fv14112404&rft.externalDocID=A746717226
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4915&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4915&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4915&client=summon